Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof

Abstract

Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma.

We claim: 
     
         1 . A pharmaceutical composition for intraocular use to treat an ocular condition, the composition comprising:
 (a) a plurality of microspheres made of a bioerodible polymer, and;   (a) a therapeutic agent selected from the group consisting of latanoprost, bimatoprost and travoprost and their salts, esters and derivatives, contained by the microspheres.   
     
     
         2 . The composition of  claim 1  wherein the microspheres comprise from about 1% to about 99% by weight of the polymer. 
     
     
         3 . The composition of  claim 2 , wherein the polymer is a PLGA. 
     
     
         4 . The composition of  claim 2  wherein the microspheres have an average greatest dimension in a range of from about 5 microns to about 1 mm. 
     
     
         5 . The composition of  claim 4  wherein the microspheres has a mean diameter between about 15 microns and about 55 microns. 
     
     
         6 . The method of  claim 5  wherein the therapeutic agent comprises from about 0.1% to about 90% by weight of the microspheres. 
     
     
         7 . The composition of  claim 6  wherein the microspheres comprise between about 8 to 15 weight % latanoprost. 
     
     
         8 . The composition of  claim 1  further comprising a high viscosity hyaluronic acid. 
     
     
         9 . The composition of  claim 1  wherein the ocular condition is glaucoma. 
     
     
         10 . A pharmaceutical composition for intraocular use to treat glaucoma, the composition comprising:
 (a) a plurality of microspheres made from a PLGA;   (b) latanoprost contained by the microspheres, and;   (c) a high viscosity hyaluronic acid.   
     
     
         11 . A method of treating glaucoma, the method comprising intraocular administration to a patient with glaucoma of a pharmaceutical composition comprising:
 (a) a plurality of microspheres made from a PLGA and/or PLA;   (b) latanoprost contained by the microspheres, and;   (c) a high viscosity hyaluronic acid, thereby treating the glaucoma.   
     
     
         12 . The method of  claim 11 , wherein the microspheres can release the latanoprost for at least about one week after the administration step. 
     
     
         13 . The method of  claim 12 , wherein the microspheres can release the latanoprost for at least about one month after the administration step. 
     
     
         14 . The method of  claim 13 , wherein the microspheres can release the latanoprost for at least about two months after the administration step. 
     
     
         15 . The method of  claim 14 , wherein the microspheres can release the latanoprost for at least about three months after the administration step. 
     
     
         16 . The method of  claim 15 , wherein the microspheres can release the latanoprost for at least about four months after the administration step. 
     
     
         17 . The method of  claim 16 , wherein the microspheres can release the latanoprost for at least about six months after the administration step. 
     
     
         18 . The method of  claim 13 , wherein the microspheres can release the latanoprost for between about one month and about six months after the administration step. 
     
     
         19 . The method of  claim 11 , the intraocular administration step is carried out by injection into the sub-tenon space. 
     
     
         20 . The method of  claim 19 , the sub tenon administration step is carried out injection into the anterior sub-tenon space. 
     
     
         21 . The method of  claim 11 , wherein the pharmaceutical composition treats glaucoma by reducing baseline intraocular pressure by up to 45%. 
     
     
         23 . A method of treating glaucoma, the method comprising anterior sub-tenon administration to a patient with glaucoma of a pharmaceutical composition comprising:
 (a) a plurality of microspheres made from a PLGA and/or PLA;   (b) latanoprost contained by the microspheres, wherein the microspheres release the latanoprost for at least about two months after the administration step, and;   (c) a high viscosity hyaluronic acid, thereby treating the glaucoma by reducing baseline intraocular pressure by up to about 45%.